When clonal plasma cells grow at anatomic sites distant from the bone marrow or grows
contiguous from osseous lesions that break through the cortical bone, it is referred to as …

This review highlights literature pertinent to chimerism analysis in the context of
hematopoietic cell transplantation (HCT). We also conducted a survey of testing practices of …

Although high-dose therapy and autologous stem cell transplant combined with novel
agents continues to be the hallmark of first-line treatment in newly diagnosed transplant …

Despite significantly improved survival and response rates in patients diagnosed with
multiple myeloma, it still remains an incurable disease with a poor outcome, especially in …

Myeloma is characterized by extensive inter-patient genomic heterogeneity due to multiple
different initiating events. A recent multi-region sequencing study demonstrated spatial …

Simple Summary Due to its graft-versus-myeloma effect, allogeneic hematopoietic stem cell
transplantation (allo-SCT) can enable long-term survival or even cure in carefully selected …

High risk multiple myeloma (HRMM) at diagnosis is currently recognized according to the
Revised International Staging System (R-ISS) which was set up in 2015. Since then, new …

Despite the introduction of novel agents such as proteasome inhibitors, immunomodulatory
drugs, and autologous stem cell transplant, multiple myeloma (MM) largely remains an …

Published experience with carfilzomib in patients with relapsed/refractory multiple myeloma
(RRMM) and extramedullary disease (EMD) is still limited. The current study aimed to …

Chimerism testing is used to monitor engraftment and risk of relapse after allogeneic
hematopoietic stem cell transplantation for hematologic malignancies. Although short …